Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) shares rose 9.9% during mid-day trading on Friday . The stock traded as high as $21.20 and last traded at $21.78. Approximately 34,633 shares traded hands during mid-day trading, a decline of 51% from the average daily volume of 70,739 shares. The stock had previously closed at $19.83.
Analyst Ratings Changes
PHVS has been the subject of several analyst reports. Guggenheim initiated coverage on shares of Pharvaris in a research note on Wednesday, June 11th. They issued a "buy" rating and a $32.00 target price for the company. Wedbush reissued an "outperform" rating and issued a $27.00 price target on shares of Pharvaris in a report on Thursday, June 5th. Finally, Cantor Fitzgerald cut their price target on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $36.20.
View Our Latest Report on Pharvaris
Pharvaris Trading Down 5.3%
The company has a market cap of $1.24 billion, a PE ratio of -7.91 and a beta of -2.82. The firm's fifty day moving average is $17.37 and its 200 day moving average is $16.71.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.09). As a group, sell-side analysts anticipate that Pharvaris N.V. will post -2.71 EPS for the current fiscal year.
Institutional Investors Weigh In On Pharvaris
A number of large investors have recently modified their holdings of the business. Deutsche Bank AG grew its holdings in shares of Pharvaris by 55.1% during the first quarter. Deutsche Bank AG now owns 28,174 shares of the company's stock worth $442,000 after buying an additional 10,006 shares in the last quarter. TD Asset Management Inc grew its holdings in shares of Pharvaris by 41.5% during the first quarter. TD Asset Management Inc now owns 78,122 shares of the company's stock worth $1,227,000 after buying an additional 22,906 shares in the last quarter. Palumbo Wealth Management LLC grew its holdings in shares of Pharvaris by 38.0% in the first quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company's stock valued at $221,000 after purchasing an additional 3,881 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Pharvaris by 30.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock valued at $1,222,000 after purchasing an additional 14,838 shares during the period. Finally, Woodline Partners LP purchased a new stake in shares of Pharvaris in the fourth quarter valued at about $853,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
